Diagnostic performance of 18F-fluciclovine PET/CT in prostate cancer patients with rising PSA level ≤ 0.5 ng/ml after multiple treatment failures
This retrospective study is to assess the performance of 18 F-Fluciclovine PET/CT in prostate cancer (PC) patients with multiple treatment failures and prostate-specific antigen (PSA) ≤ 0.5 ng/mL. PC patients with multiple treatment failures who had PSA level within 2-week interval of 18 F-Fluciclov...
Gespeichert in:
Veröffentlicht in: | American journal of nuclear medicine and molecular imaging 2021-04, Vol.11 (2), p.87-98 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | This retrospective study is to assess the performance of
18
F-Fluciclovine PET/CT in prostate cancer (PC) patients with multiple treatment failures and prostate-specific antigen (PSA) ≤ 0.5 ng/mL. PC patients with multiple treatment failures who had PSA level within 2-week interval of
18
F-Fluciclovine PET/CT (PSA
PET
) ≤ 0.5 ng/mL were identified in retrospective review of our institution’s database (n=28). Patient, tumor, treatment, PSA and castration characteristics as well as findings on
18
F-Fluciclovine PET/CT were collected and compared between positive and negative
18
F-Fluciclovine PET/CT subgroups by using Fisher’s exact test. The overall detection rate of
18
F-Fluciclovine PET/CT was 7 of 28 studies (25%). PSA
PET
> 0.2 ng/mL was associated with higher detection rates in all (33.3 vs 10%,
P
=0.172), castration-resistant (CR) (50 vs 20%,
P
=0.343) and castration-sensitive (CS) (28.6 vs 0%,
P
=0.179) patients. Sites of recurrence were local 42.9% (3/7), nodal 42.9% (3/7) and bone metastases 14.3% (1/7). Higher Gleason score (GS 8-10) (33.3 vs 14.5%,
P
=0.396), advanced tumor stage (T3-T4) (35.7 vs 20%,
P
=0.653), second-line androgen deprivation therapy (ADT) uses (66.7 vs 20%,
P
=0.145), chemotherapy uses (50 vs 23.1%,
P
=0.444) and CRPC (33.3 vs 21.1%,
P
=0.483) related to positivity of
18
F-Fluciclovine PET/CT but none reached statistical significance. Performance of
18
F-Fluciclovine PET/CT in prostate cancer patients with multiple treatment failures and PSA
PET
≤ 0.5 ng/mL was acceptable particularly in patients with PSA
PET
≥ 0.3 ng/mL, CRPC, initial GS ≥ 8 or T3-T4. |
---|---|
ISSN: | 2160-8407 2160-8407 |